Media Minds Roundtable Event: The China Biopharma Scene — Topics & Issues Journalists Are Watching in 2026-2027

Drew Armstrong has served as the Executive Editor of Endpoints News since 2022, where he leads the newsroom’s editorial operations and strategy. He has nearly two decades of experience as a health care journalist in New York and Washington, DC. His and his team’s work has been recognized by multiple journalism awards, and he has appeared regularly on television and radio. His prior experience includes a 12-year career at Bloomberg News. There, he led the newsroom’s U.S. coverage of the Covid-19 pandemic, developed its “Prognosis” health care vertical and managed a team of a dozen journalists covering every aspect of the American healthcare system. Prior to Bloomberg, he spent five years covering US health policy at Congressional Quarterly. He lives in the New York City area with his family. Have a confidential tip? Reach out privately on Signal: DrewArmstrong.39

Angus is a deputy editor with Questex’s Life Sciences group. He earned his Master’s at Northwestern University’s Medill School of Journalism, where he worked as a health reporter besides learning pertinent skills in magazine editing and interactive production. Prior to Medill, he worked as a reporter for an online news publication in China for two years, covering general city news; he also used to work for an international travel agency before pursuing a career in journalism. Angus loves classical music and traveling in his spare time.

Guy Martin is Deputy News Editor at The Pharma Letter, a leading global news and intelligence service covering the pharmaceutical, biotech and life sciences sectors. He has been a journalist since 2008, and has covered pharma and biotech since 2016, reporting across company strategies, commercial trends, regulatory developments, clinical data and innovation in emerging technologies that are shaping industry evolution.

At The Pharma Letter, Guy oversees editorial coverage and contributes in-depth analysis, feature articles and interviews that help senior executives, investors and communications teams understand key industry movements, milestone events and strategic implications for companies and market dynamics. His work spans news, commentary and analytical pieces that interpret developments in R&D, partnerships, policy, and commercial strategy.

Guy regularly engages with senior communicators, corporate leaders and sector stakeholders on how best to position scientific, strategic and commercial narratives within trusted industry channels. He also participates as a speaker at life sciences events, bringing editorial perspective to topics such as innovation leadership and biotech ecosystem trends.

Before joining The Pharma Letter, Guy built experience reporting across local news, sport and transport. He is based in London, UK.